The Barcelona Clinic Liver Cancer (BCLC) staging system is widely recognized as a prognostic tool for HCC. However, despite many updates, the BCLC staging system has several limitations and shortcomings, including ambiguity about underlying liver disease and a lack of subdivisions in advanced and terminal stages.
The INASL has modified the existing BCLC staging system to address these limitations. The INASL-BCLC system offers clarity, specifying its application to HCC patients with liver cirrhosis. It subdivides stages C and D to cater to varied patient needs, emphasizing the role of locoregional therapy and potential liver transplantation. While the BCLC overlooks combination therapies and downstaging, the INASL-BCLC recognizes their importance and integrates treatments like Transarterial Radioembolization (TARE) and Stereotactic Body Radiation Therapy (SBRT). Overall, the INASL-BCLC offers a more nuanced approach to HCC management than BCLC. Table 1 provides a comparative analysis between the BCLC staging and the INASL modification of BCLC staging for hepatocellular carcinoma (HCC).
INASL recommends the use of the 'INASL modification of the BCLC staging system (INASL-BCLC Staging)' for improved prognosis prediction and treatment of HCC in India and Asia.
Негізгі бет Pragmatic Staging of Hepatocellular Carcinoma (Liver Cancer)
Пікірлер: 3